PRLD Prelude Therapeutics Inc revenue, earnings and financials
For the quarter ended June 30, 2026, Prelude Therapeutics Inc reported revenue of $5.70M, net income of −$13.9M and diluted EPS of −$0.14; over the last four quarters revenue was $22.4M and net income −$60.5M; for the fiscal year ended December 2025 revenue was $12.1M, up 73.4% on the year before.
PRLD annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $12.1M, gross profit n/a, operating income −$105M, net income −$99.5M (margin -819.6%), EPS −$1.29
- Fiscal year ended Dec 2024: revenue $7.00M, gross profit n/a, operating income −$140M, net income −$127M (margin -1816.7%), EPS −$1.68
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$132M, net income −$122M (margin n/a), EPS −$2.02
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$124M, net income −$115M (margin n/a), EPS −$2.44
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$114M, net income −$112M (margin n/a), EPS −$2.43
PRLD quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $5.70M, net income −$13.9M, EPS −$0.14
- Quarter ended Mar 31, 2026: revenue $4.58M, net income −$10.4M, EPS −$0.13
- Quarter ended Dec 31, 2025 (from the annual report): revenue $5.64M, net income −$16.5M, EPS −$0.20
- Quarter ended Sep 30, 2025: revenue $6.50M (up 116.7% year over year), net income −$19.7M, EPS −$0.26
- Quarter ended Jun 30, 2025: revenue $0, net income −$31.2M, EPS −$0.41
- Quarter ended Mar 31, 2025: revenue $0, net income −$32.1M, EPS −$0.42
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$28.7M, EPS −$0.37
- Quarter ended Sep 30, 2024: revenue $3.00M, net income −$32.3M, EPS −$0.43
- Quarter ended Jun 30, 2024: revenue n/a, net income −$34.7M, EPS −$0.46
- Quarter ended Mar 31, 2024: revenue n/a, net income −$31.4M, EPS −$0.42
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$33.1M, EPS −$0.45
- Quarter ended Sep 30, 2023: revenue n/a, net income −$30.6M, EPS −$0.45
- Quarter ended Jun 30, 2023: revenue n/a, net income −$30.4M, EPS −$0.54
- Quarter ended Mar 31, 2023: revenue n/a, net income −$27.7M, EPS −$0.58
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$28.6M, EPS −$0.60
- Quarter ended Sep 30, 2022: revenue n/a, net income −$30.0M, EPS −$0.63
- Quarter ended Jun 30, 2022: revenue n/a, net income −$27.4M, EPS −$0.58
- Quarter ended Mar 31, 2022: revenue n/a, net income −$29.5M, EPS −$0.63
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$32.8M, EPS −$0.72
- Quarter ended Sep 30, 2021: revenue n/a, net income −$30.7M, EPS −$0.66
PRLD cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$56.3M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$103M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$107M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$83.7M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$83.5M, share buybacks n/a
PRLD balance sheet
- Jun 30, 2026: cash $26.3M, total assets $189M, total liabilities $55.6M, shareholders' equity $134M
- Mar 31, 2026: cash $21.8M, total assets $120M, total liabilities $59.5M, shareholders' equity $60.2M
- Dec 31, 2025: cash $35.3M, total assets $141M, total liabilities $72.7M, shareholders' equity $68.6M
- Sep 30, 2025: cash $47.5M, total assets $94.8M, total liabilities $36.2M, shareholders' equity $58.5M
- Jun 30, 2025: cash $25.8M, total assets $115M, total liabilities $39.1M, shareholders' equity $75.8M
- Mar 31, 2025: cash $40.3M, total assets $141M, total liabilities $38.1M, shareholders' equity $103M
- Dec 31, 2024: cash $12.5M, total assets $176M, total liabilities $44.1M, shareholders' equity $131M
- Sep 30, 2024: cash $11.1M, total assets $197M, total liabilities $40.8M, shareholders' equity $156M
What is PRLD's revenue?
Prelude Therapeutics Inc reported $22.4M of revenue over its last four quarters, through June 30, 2026.
Is PRLD profitable?
No. Prelude Therapeutics Inc lost $60.5M over the last four quarters.
What is PRLD's EPS?
Diluted earnings per share over the last four quarters were −$0.73; −$0.14 in the latest quarter.